---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-26-000076"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:26:04.738000+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PacBio Q1 rev flat at $37.2M; consumable record but instrument miss; FY26 guidance $165-175M

## Summary
- Q1 revenue $37.2M flat YoY; consumable record $21.8M (+8% YoY), instrument revenue $9.7M (-12% YoY) below expectations.
- GAAP net loss $8.3M ($0.03/sh) vs $426.1M loss ($1.44/sh) in Q1 2025 (incl. restructuring); non-GAAP loss $35.9M ($0.12/sh).
- Full year 2026 revenue guidance $165M-$175M; cash $276M after $48.1M net from short-read asset sale.
- SPRQ-Nx beta to broad Revio launch in May; Basecamp Research project for ~100K samples selected PacBio.
- EMEA revenue +17% YoY; non-GAAP gross margin 37% vs 40% on component costs and promotions.

## SEC filing metadata
- accession: 0001299130-26-000076
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000076/0001299130-26-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000076/pacb-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-26-000076
- JSON: https://secwatch.observer/filing/0001299130-26-000076.json
- Plain text: https://secwatch.observer/filing/0001299130-26-000076.txt

## Source-grounded claims
- claim_id: 0fed28391e9de8bae055fa7b375a766864e5feaf
  claim: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported for its first fiscal quarter ended March 31, 2026 results: revenue $37.2, net income GAAP net loss for the first quarter of 2026 was $8.3 million, EPS GAAP net loss per share for the first quarter of 2026 was $0.03. Guidance reaffirmed.
  evidence_excerpt: which has the potential to produce the largest and most diverse high-fidelity metagenomic dataset in the world." First quarter results: Q1 2026 Q1 2025 Revenue (in millions) $37.2 $37.2 Consumable revenue (in millions) $21.8 $20.1 Instrument revenue (in millions) $9.7 $11.0 Service and other revenue (in millions) $5.6 $6.0 Revio TM system placements 15 12
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913026000076/0001299130-26-000076-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.